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Abstract
Background: Aquaporins (AQP) are water channel proteins that enable fluid fluxes across cell membranes,
important for homeostasis of the tissue environment and for cell migration. AQP1 knockout mouse models of
human cancers showed marked inhibition of tumor-induced angiogenesis, and in pre-clinical studies of colon
adenocarcinomas, forced over-expression of AQP1 was shown to increase angiogenesis, invasion and metastasis.
We have synthesized small molecule antagonists of AQP1. Our hypothesis is that inhibition of AQP1 will reduce
migration and invasiveness of colon cancer cells, and the migration and tube-forming capacity of endothelial cells
in vitro.
Methods: Expression of AQP1 in cell lines was assessed by quantitative (q) PCR, western blot and
immunofluorescence, while expression of AQP1 in human colon tumour tissue was assessed by
immunohistochemistry. The effect of varying concentrations of the AQP1 inhibitor AqB013 was tested on human
colon cancer cell lines expressing high versus low levels of AQP1, using wound closure (migration) assays, matrigel
invasion assays, and proliferation assays. The effect of AqB013 on angiogenesis was tested using an endothelial cell
tube-formation assay.
Results: HT29 colon cancer cells with high AQP1 levels showed significant inhibition of migration compared to
vehicle control of 27.9 % ± 2.6 % (p < 0.0001) and 41.2 % ± 2.7 (p <0.0001) treated with 160 or 320 μM AqB013
respectively, whereas there was no effect on migration of HCT-116 cells with low AQP1 expression. In an invasion
assay, HT29 cells treated with 160 μM of AqB013, showed a 60.3 % ± 8.5 % decrease in invasion at 144 hours
(p < 0.0001) and significantly decreased rate of invasion compared with the vehicle control (F-test, p = 0.001).
Almost complete inhibition of endothelial tube formation (angiogenesis assay) was achieved at 80 μM AqB013
compared to vehicle control (p < 0.0001).
Conclusion: These data provide good evidence for further testing of the inhibitor as a therapeutic agent in
colon cancer.
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Background
Colorectal cancer (CRC) is the third most commonly di-
agnosed cancer and the third leading cause of death
resulting from cancer in the USA [1]. In Australia it is
the second most commonly reported cancer diagnosis
after prostate cancer, and the second leading cause of
death after lung cancer [2]. A major determinant of pa-
tient prognosis is the stage at which the cancer is diag-
nosed, as surgery is considered curative in up to 70 % of
early stage cases. Screening programs have helped with
early diagnosis and intervention, but for those not par-
ticipating in such programs some 12-25 % of CRC pa-
tients still present with advanced (stage IV) disease [3].
Furthermore, up to 30 % of patients diagnosed with early
localised CRC (stage I or II) and up to 50 % with re-
gional spread to lymph nodes or adjacent organs (stage
III) eventually relapse with overt metastatic disease fol-
lowing ‘curative’ surgery [4]. Adjuvant chemotherapy is
offered to stage III patients to eradicate potentially exist-
ing micro-metastases but the indication for such treat-
ment in stage II disease is less certain where the benefit
shown in clinical trials is small in absolute terms and
thus the risk of fluorouracil toxicity likely outweighs the
benefit [5]. The dilemma is finding a balance between
the benefit of therapy, which may be incremental, and
risk of harm, and to that end discovery of new thera-
peutic targets and pharmacological agents is a continu-
ing goal for improving adjuvant cancer therapy.
Aquaporins (AQP) and their role in cancer progression
Mammalian aquaporins are a family of 13 classes of in-
trinsic membrane proteins that assemble as tetramers
(~30 kDa per subunit) and are known for their role in
fluid homeostasis and trans-membrane transport of
water and other small solutes [6, 7]. Specific classes of
AQP channels have been implicated in enhanced migra-
tion, angiogenesis and metastasis in a variety of cancer
types [8, 9], prompting the suggestion that inhibitors of
AQP channels might provide new tools for cancer ther-
apy [8]. The role of AQP1 in tumour migration and
angiogenesis was first demonstrated in a murine melan-
oma tumour model: in AQP1 null mice tumours were
smaller with fewer micro-vessels and more extensive ne-
crosis as compared to AQP1 wild type mice, suggesting
that AQP1 deletion impaired endothelial cell prolifera-
tion and angiogenesis [10]. AQP1 involvement in angio-
genesis has been confirmed in other studies: in a murine
melanoma tumour model, mice treated with AQP1 short
interfering (si) RNA had significantly smaller tumours
and lower microvessel and endothelial marker (factor
VIII) densities compared to control mice, suggesting
AQP1 knockdown impaired tumour growth and angio-
genesis [11]. In mice with genetic deletion of AQP1,
microvessel density was significantly reduced and also
the number of lung metastases (5 ± 1/mouse) as com-
pared with AQP1-expressing mice from the same gen-
etic background (31 ± 8/mouse, P < 0.005) [12]. Colon
tumour cells over-expressing AQP1 exhibited increased
migratory and invasive capacity in wound healing (mi-
gration) and transwell invasion assays [13]. Over-
expression of AQP1 in tumour cell lines resulted not
only in a predicted increase in cell membrane water per-
meability, but also a 2 to 3-fold accelerated migration
rate of the AQP1-expressing tumour cells as compared
to control cells in vitro. AQP1 over-expression in mice
increased the extravasation of tumour cells injected via
the tail vein compared to control mice, and increased by
3-fold the number of lung metastases [14].
It is through enhanced water flux mediated by the AQP
channels that cells are believed to acquire an enhanced
migratory and invasive phenotype [13, 15]. Interestingly,
AQP1 has been shown by our group to have dual water
channel and gated ion channel functions [16, 17]. The
AQP blocker AqB013, a derivative of bumetanide, has
been characterised as a dose-dependent inhibitor of os-
motic water fluxes mediated by mammalian AQP1 and
AQP4 channels analysed in the Xenopus laevis expression
system. AqB013 was shown to inhibit the AQP1 water
channel function when applied extracellularly, and is
thought to cross the membrane to occlude the water
channel pore from the cytoplasmic side of the AQP1
channel [18]. Work here is the first to test the efficacy of
AqB013 in inhibiting migration, invasion and angiogenesis
in colon cancer cell line models.
Methods
Cell lines and cell culture
HT29 and HCT-116 colon cancer cell lines (ATCC,
Manassas, USA) were cultured in complete medium com-
posed of DMEM (Life Technologies, Carlsbad, CA, USA)
supplemented with 1 x glutaMAX™ (Life Technologies), 1
x penicillin-streptomycin solution (Life Technologies) and
10 % foetal bovine serum (FBS). Cultures were maintained
in 5 % CO2 at 37 °C. Their authenticity was confirmed
(CellBank Australia, Melbourne, Vic). Human umbilical
vein endothelial cells (HUVEC) (PromoCell, Heidelberg,
Germany) were cultured in endothelial growth medium
(PromoCell) according to the protocol supplied, and
maintained in 5 % CO2 at 37 °C. Cells were confirmed to
be negative for mycoplasma using the Universal Myco-
plasma Detection kit (ATCC) according to the manufac-
turer's protocol.
Colon tissue samples
Human colon tumour and matched normal mucosal tis-
sue samples were obtained from 57 patients undergoing
surgery for CRC at The Queen Elizabeth Hospital. The
protocol was approved by The Queen Elizabeth Hospital
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Ethics of Human Research Committee (approval no.
1993059) and informed consent was obtained in all
cases.
Expression analysis of AQP1
Quantitative PCR
Cells at 70-80 % confluence were harvested and RNA
extracted using the PureLink™ RNA Mini kit (Life Tech-
nologies). RNA was extracted from the frozen archived
colon tumour and matched normal mucosa samples by
pulverizing tissue under liquid nitrogen, and extracting
RNA as before. RNA concentration was quantified using
the NanoDrop 2000 spectrophotometer (Thermo Scien-
tific, Waltham, MA, USA) and the integrity (RIN score)
assessed using the 2100 Bioanalyzer (Agilent Technolo-
gies, Santa Clara, CA, USA). RNA (500 ng) was reverse
transcribed using the iScript™ cDNA synthesis kit (Bio-
rad, Carlsbad, CA, USA). qPCR of AQP1 and the refer-
ence gene phosphomannose mutase 1 (PMM1) [19] was
performed using multiplex Taqman expression assays
(Life Technologies), in triplicate via the CFX96™ Ther-
mal Cycler (Bio-Rad). Each reaction contained 0.75 μL
of each TaqMan® Gene Expression Assay (Life Technolo-
gies), 2 μL cDNA, 4.0 μL ultrapure water (Fisher Biotec,
Wembley, WA, Australia) and 7.5 μL SsoFast™ probes
supermix (Bio-rad) in a total volume of 15 μL. Results
were calculated according to the 2-ΔΔCt relative quantifi-
cation method.
Western blot
Cells were lysed with RIPA buffer containing 1 % β-
mercaptoethanol, 1 % HALT protease inhibitor 100X so-
lution, 150 U Benzonase (all from Sigma, St Louis, MO,
USA) on ice for 10 minutes, homogenized by passing
through a 21 gauge needle and centrifuged at 14,000 x g
for 15 minutes at 4 °C to pellet the cell debris. As AQP1
can be glycosylated [20], the supernatant was treated
with PNGaseF (Promega, Madison, WI, USA) to cleave
N-linked oligosaccharides. Protein was quantified (EZQ®
assay, Life Technologies) and 50 μg of each sample was
resolved by SDS-PAGE on a 12 % Mini-Protean® TGX
Stain-Free™ Gels (Bio-Rad) and transferred to PVDF
membranes using the Trans-Blot® Turbo™ Transfer Pack
and System (Bio-Rad). Membranes were blocked with
TBST containing 5 % skim milk for 1 hour and incu-
bated overnight at 4 °C with anti-AQP1 rabbit polyclonal
(H-55) (1/500; Santa Cruz Biotechnology Inc, Santa
Cruz, CA, USA). Following three washes in TBST, mem-
branes were incubated with goat anti-rabbit IgG HRP
secondary antibody (1/2000) and Streptactin-HRP
Conjugate (1/10000) (both from Bio-Rad) at room
temperature for 1 hour, and washed. Chemilumines-
cence substrate was applied (Clarity™ Western ECL
Blotting Substrate, Bio-Rad) and blots analysed using the
ChemiDoc™ Touch Imaging System (Bio-Rad). Image
Lab™ Software (Bio-Rad) was used for relative quantifica-
tion of bands, normalized to total protein loaded in each
lane.
Immunofluorescence
Cells grown on coverslips at 80 % confluence were fixed
with 4 % paraformaldehyde and permeabilized with 0.5
% triton X-100. Image-iT® FX Signal Enhancer (Life
Technologies) was applied directly to cover slips in ac-
cordance with manufacturer’s instructions. Cells were
stained with a 1/400 dilution of rabbit polyclonal anti-
human AQP1 (Abcam®, Cambridge, UK) and for the
antibody isotype matched control, a 1/400 dilution of
normal rabbit IgG was used (Cell Signaling Technology,
Beverly, MA, USA). Cells were then stained with a 1/200
dilution of goat anti rabbit IgG H&L (Alexa Fluor® 568)
secondary antibody (orange fluorescence) and the nuclei
stained with NucBlue® Fixed Cell Ready Probes™ Reagent
(blue fluorescence) (both from Life Technologies).
Coverslips were mounted on slides with ProLong® Gold
antifade reagent (Life Technologies), and images cap-
tured using the Zeiss LSM 700 microscope (Carl Zeiss
Microscopy, Jena, Germany).
Immunohistochemistry
Tissue sections (5 μm) were deparaffinised by heating at
55-60 °C for 2 hours, soaking in xylene and hydrating by
passing through a graded series of ethanol to water.
Antigen retrieval was carried out by microwaving the
slides in 10 mM sodium citrate for 20 mins. Endogenous
peroxidase was quenched by incubating the slides in
Peroxidazed I reagent (Biocare Medical, Concord, CA,
USA) for 5 min and background staining was blocked by
incubation in Background Sniper reagent (Biocare
Medical). Slides were stained using a 1:100 dilution of
AQP1 monoclonal antibody 10C11 (Abcam, Cambridge,
UK) and detected using the MACH 3™ mouse HRP poly-
mer detection system according to the manufacturer’s
protocol (Biocare Medical). Slides were counterstained
in haematoxylin (Sigma-Aldrich, St Louis, MO, USA).
AQP1 inhibitor and vehicle control
AqB013 was dissolved in dimethyl sulfoxide (DMSO) at
a 100 mM (stock solution), which was diluted into
complete medium to yield the indicated working con-
centrations for the experiments. DMSO was used as the
vehicle control at a dilution equivalent to that in the
highest dose of the drug used in the treatments.
Effect of AQP1 inhibition on cell migration (wound
healing assay)
HT29 or HCT-116 cells were grown in complete
medium (DMEM with 10 % FCS) to 80-90 % confluence
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in triplicate wells of a 24-well untreated plastic tissue
culture plate, serum starved overnight, then treated with
1 μg/mL mitomycin C in complete medium to prevent
cells from proliferating. Wells were treated with increas-
ing amounts of the inhibitor with vehicle (DMSO) as
control. A p10 pipette tip was used to scratch a wound
through the cell monolayer and cells were monitored as
they migrated across the wound using a Nikon Eclipse
microscope (40X magnification) at time 0, 16, 32, 48, 64
and 80 hours: 20 measurements were taken of the
wound width at each time point using the NIS-Elements
software and averaged. Wound closure was calculated as
a percentage relative to the initial wound width.
Spheroid basement membrane extract (BME) invasion
assay
Cells were cultured into spheres in an ultra-low attach-
ment plate according to the manufacturer's protocol
(Cultrex® 3D 96 Well Spheroid BME Cell Invasion
Assay, Trevigen™), then covered with Invasion Matrix (a
proprietary extracellular matrix blend comprised of
basement membrane extract, derived from murine EHS
sarcoma cells and collagen) together with the inhibitor
AqB013 from 0 (untreated) to 160 μM, and with vehicle
control. The area of the sphere was measured at each
time point to assess invasion into the surrounding
matrix, using the NIS-Elements software. The change in
sphere area was calculated as a percentage relative to the
initial sphere size; percent invasion of the test sphere
was subtracted from the percent invasion of the vehicle
control to indicate the extent of invasion into the
matrix.
Cell proliferation assay
HT29, HCT-116 or HUVEC were grown overnight, then
AqB013 was added to triplicate wells from 0 (untreated)
up to 320 μM. DMSO was added to triplicate wells as
vehicle control. Proliferation was quantified after 48
hours using the Cell Titer 96® Aqueous Non- Radio-
active cell Proliferation Assay (Promega) and absorbance
at 490 nm read on a FLUOstar OPTIMA 96 well micro-
plate reader (BMG Lab Tech, Ortenberg, Germany).
Angiogenesis assay
Human umbilical vein endothelial cells (HUVECs) were
seeded at 1 x 104 cells per well in a 96 well plate pre-
coated with BME (basement membrane extract: recon-
stituted protein matrix comprised of laminin, collagen
IV, entactin, and heparin sulphate proteoglycan) and in-
cubated in endothelial growth medium (PromoCell,
Heidelberg, Germany) containing VEGF according to
the Cultrex In Vitro Angiogenesis Assay Kit protocol
(Trevigen, Gaithersburg, MD, USA). Wells were treated
in triplicate with AqB013 from 0 (untreated) to 80 μM
and with vehicle as a control. Cells were stained with
Calcein AM dye at 24 hrs and imaged using a Nikon
Eclipse fluorescence microscope. Endothelial tube for-
mation was quantified as the number of junctions
formed.
Statistical analysis
Statistical analysis was carried out in Graph Pad® prism
5. A one-way ANOVA with Tukey’s multiple compari-
sons test was carried out for qRT-PCR results, for prolif-
eration assays and for the angiogenesis assays. For the
migration and invasion assays, a two-way ANOVA was
performed to determine the significance between the
data points of the final time point, also a first order poly-
nomial regression was fitted to the data sets and an F-
test used to determine significance (p < 0.05). Statistical
significance was accepted at p < 0.05.
Results
Expression of AQP1
Of the cell lines, the human umbilical vein endothelial
cells (HUVEC) showed the highest expression of AQP1,
HT29 showed a moderate level of expression, while
HCT-116 showed a low level of expression. The range of
expression levels was similar to that found in patients'
tumour samples (Fig. 1a). Using the 2-ΔΔCt relative quan-
tification method, AQP1 was over-expressed (by >1.6-
fold) in 22/57 (39 %) colon tumours compared to
matched normal mucosa (Fig. 1b). Western blot (Fig. 1c)
shows bands at approximately 28 KDa and relative quan-
tification confirmed that AQP1 expression in HCT-116
cells was reduced by 67 % compared to HT29 cells, and
by 72 % compared to HUVEC (Fig. 1d). Immunofluores-
cence staining showed both cytoplasmic and membrane
AQP1 expression in HT29 cells (Fig. 1e). Immunohisto-
chemistry of colon tumour sections showed that AQP1
is expressed variably in the apical membrane and in the
cytoplasm. The range in staining for AQP1 concurs with
the range of expression levels in tumour tissue at the
mRNA level (Fig. 1a). In malignant crypt epithelial cells
the expression of AQP1 varies from low intensity 1+
(Fig. 1f ), moderate intensity 2+ (Fig. 1g) and high inten-
sity 3 + (Fig. 1h): Endothelial cells of the micro-vessels
show high staining intensity (arrows in Fig. 1 f–h) and
reflects the high expression of AQP1 in endothelial cells
at the mRNA level (HUVEC Fig. 1a).
Treatment with AqB013 slows migration of colon cancer
cells expressing significant amounts of AQP1
At the final time-point HT29 cells treated with 160 μM
or 320 μM AqB013 had a significantly reduced wound
closure compared to vehicle control of 27.9 % ± 2.6 % (p
< 0.0001) and 41.2 % ± 2.7 (p <0.0001) respectively (2-
way ANOVA with Bonferroni post hoc test) (Fig. 2a).
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The dose response curve showed that the IC50 was
132.7 μM, Hill Slope -2.8. Treatment of HCT-116 cells
(low level of AQP1 expression) with AqB013 showed no
significant effect on migration (Fig. 2b).
Treatment with AqB013 reduces invasion of colon cancer
cells
The area of the spheres was measured as the cells in-
vaded the surrounding matrix. For HT29 spheres
treated with 80 μM or 160 μM of AqB013, there was
a 59.5 % ± 1.4 % (p = 0.0003) or 60.3 % ± 8.5 % (p <
0.0001) decrease in invasion respectively at 144 hours
compared to the vehicle control (Fig. 2c). A reduced
rate of invasion was also found compared to the ve-
hicle control (F-test, p = 0.001). The IC50 was 55.6
μM, Hill Slope -5.17. Treatment of HCT-116 with
AqB013 showed no significant effect on spheroid in-
vasion (Fig. 2d). There was no appreciable cytotoxic
effect as there was no effect on proliferation of HCT-
116 at concentrations of AqB013 up to 320 μM, al-
though there was a small decrease in proliferation of



































































































Fig. 1 AQP1 expression. (a) relative expression of AQP1 (qPCR) in HUVEC, colon cancer cell lines, and human colon tumours (error bars show
mean ± SEM; ** p = 0.004 ANOVA); (b) relative expression of AQP1 in CRC patients’ tumours compared to their matched normal mucosa. (c)
western blot showing AQP1 monomer: lane 1 HUVEC, lane 2 HCT-116, lane 3 HT29. (d) corresponding quantification of bands using Image Lab™
Software (Bio-Rad); (e) immunofluorescence (IF) of HT29 colon cancer cells stained with anti-AQP1 and goat anti-rabbit secondary–Alexa 468
conjugate (orange) with NucBlue® stained nuclei overlay (63 x objective, scale bar = 10 μm). (f, g, h) immunohistochemistry of colon tumour
sections staining for AQP1: F low, G moderate, H high expression. Arrows show examples of strong AQP1 staining of microvessels (20 x objective,
scale bar = 0.1 mm)
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Treatment of endothelial cells with AqB013 markedly
inhibits tube formation
Compared to vehicle control, treatment of HUVECs
with 40 μM AqB013, showed a 43 % reduction in the
number of junctions formed (34.0 ± 3.0, p < 0.01) while
treatment with 80 μM AqB013 resulted in a reduction of
89.5 % (6.3 ± 2.4, p < 0.0001) (Fig. 3a–d). As expected
there was no significant difference in the number of
junctions formed between untreated and vehicle treated
HUVECs (64.3 ± 3.0 versus 60 ± 2.5 respectively) (Fig. 3e).
There was no effect on viability or proliferation of
HUVEC treated at up to 80 μM AqB013 (Fig. 3f ).
Discussion
Small molecule pharmaceuticals have an established
therapeutic use and our team has synthesised an AQP
inhibitor, based on bumetanide [21], that blocks AQP1-
mediated water flux [18]. Bumetanide is a loop diuretic
that has long been used to treat patients with oedema
[22]. Furthermore the incidence of clinically significant
side-effects of bumetanide therapy is very low compared
to that associated with chemotherapy drugs currently
given as adjuvant therapy for CRC, making it an attract-
ive alternative to current chemotherapeutics. AQP1 has




Fig. 2 Migration and invasion. a, HT29 cells treated with 160 μM or 320 μM AqB013 had a significantly reduced migration compared to vehicle
control. b, HCT-116 cells treated with up to 320 μM AqB013 showed no significant effect on wound closure. c, the effect of AqB013 on HT29 cell
invasion (n = 3) measured by an increase in sphere size (%) relative to vehicle control: in spheres treated with 80 μM or 160 μM of AqB013 there
was a significant decrease in invasion at 144 hours compared with vehicle. d, HCT-116 cells treated with up to 320 μM AqB013 (n = 3) showed no
significant effect on invasion. ** p = 0.004; ***p < 0.001 ****p < 0.0001. e, AqB013 treatment up to 320 μM had no effect on cell proliferation of
HCT-116, at 160 μM AqB013 HT29 showed 17% reduced proliferation (*p = 0.03 ANOVA). Proliferation measured in absorbance units at 490 nm.
The error bars show standard error of the mean
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models and may thus serve as a potential target for small
molecule inhibitors to treat cancer in subgroups express-
ing AQP1. The in vitro testing of drugs is the first step
in establishing the efficacy of targeting specific mole-
cules in abrogating the migration and invasion of cancer
cells, or in suppressing angiogenesis.
In this study, inhibition of AQP1 by the inhibitor
AqB013 was effective in reducing migration (wound
closure assay) and invasion (spheroid formation assay) in
the high AQP1-expressing HT29 cells, while not affect-
ing migration or invasion in HCT-116 cells that had
much lower expression of AQP1. As both untreated and
vehicle-treated HT29 and HCT-116 cells showed similar
efficiency of wound closure and invasion, these results
suggest that AQP1 was indeed the target of inhibition.
In breast cancer cells, AQP5 polarizes to the leading
edge of migrating MDA-MB-231 cells, and that knock-
down of AQP5 in these cells significantly suppressed cell
migration velocity in narrow channels [23]. Similarly,
knockdown of AQP5 in MCF7 breast cancer cells re-
sulted in significantly reduced proliferation and migra-
tion [24]. However we have shown that the expression
of AQP5 in HCT-116 is low (Additional file 1), similar




Fig. 3 Angiogenesis assay. HUVEC tube-forming assay measured by the number of junctions: a, untreated HUVEC; b, vehicle treated HUVEC; c,
HUVEC treated with 40 μM AqB013; d, HUVEC treated with 80 μM AqB013 (40 x magnification, scale bar = 0.5 mm); e, graph shows significant
inhibition of endothelial tube formation by AqB013 at 40 μM and 80 μM, **p <0.01, ****p < 0.0001 respectively (ANOVA). f, AqB013 treatment had
no effect on proliferation of HUVECs
Dorward et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:36 Page 7 of 9
alternative mechanism of migration is used which would
explain why these cells are resistant to the inhibitory ef-
fect of AqB013. Migration in HCT-116 cells that express
low amounts of AQP1 and AQP5 may be enhanced by
expression of the calcium activated chloride channel
TMEM16A as it has recently been reported that the
high metastatic-potential colon cancer cell lines HCT-
116 and SW620 express TMEM16A while primary colon
cancer cell lines HCT8 and SW480 cells do not. Knock-
down of TMEM16A by short hairpin RNA in SW620
resulted in significantly reduced migration in wound-
closure assays [25]. In addition HCT-116 cells have been
shown to have high levels of micro RNA 224 which has
recently been shown to activate the Wnt-β catenin path-
way to promote migration and invasion of HCT-116
cells [26, 27], rendering the cells resistant to the effects
of AQP inhibition.
AQP1 has been shown to have dual water channel and
gated ion channel functions [16, 28, 29]. The AQP1-
mediated cationic conductance has been implicated in
influencing rates of net fluid transport in primary cul-
tures of choroid plexus [30], and similarly this mechan-
ism may be responsible for regulating net fluid flux in
migrating epithelial and endothelial cells. However work
by the Yool group has previously shown that endogen-
ous chloride conductance in X. laevis oocytes is not
blocked by AqB013. Furthermore in mouse intact gastric
antral muscle, the addition of AqB013 did not change
the resting membrane potential and had no substantial
effect on the rhythmic electrical conduction properties
[18]. Taken together these data suggest that the effect of
AqB013 on impeding the migration of human colon
cancer cells and endothelial cells expressing AQP1 is
mediated by blocking the water channel activity of
AQP1.
Conclusions
These studies have shown clear links between AQP1 ac-
tivity and cancer cell migration and invasion, and endo-
thelial cell tube–forming capacity, indicating the
importance of characterising suitable AQP1 blockers.
This study provides preliminary data showing that the
AQP1 inhibitor AqB013 abrogates endothelial tube for-
mation and reduces cancer cell migration and invasion
and will be further investigated in an in vivo mouse
xenotransplant model of human colon cancer. Small
molecule pharmaceuticals have an established thera-
peutic use and as this new drug is a modification of bu-
metanide, it should be well-tolerated in cancer patients
with far fewer side-effects than from currently used che-
motherapeutic drugs. Furthermore, in view of the docu-
mented role of AQP1 in murine tumour angiogenesis
[10, 12], it is envisaged that in metastatic CRC patients,
AQP1 inhibitors may have a role combined with anti-
vascular endothelial growth factor (VEGF) therapy, or as
an alternative anti-angiogenesis therapy in cases that be-
come resistant to anti-VEGF therapy. The inhibition of
AQP1 clinically may slow down the progression of CRC,
increasing the window for optimal treatment resulting in
better survival outcomes, particularly in early stage cases
where micro-metastatic disease is present.
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Additional file 1: Expression of AQP1 and AQP5. qPCR (2-ΔCt) results
normalised to reference gene PMM1. (PDF 95 kb)
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